Charcot-Marie-Tooth Disease Type 1A (CMT1A) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
_page-0001.jpg)
Charcot-Marie-Tooth disease type 1 (CMT1) is a collection of demyelinating peripheral neuropathies inherited autosomal dominant. It is characterized by weakness and wasting of muscles in the distal regions of the body, loss of sensation, foot deformities, and reduced nerve conduction velocity. The age at which CMT1 manifests can vary significantly, ranging from infancy to the fourth decade or later. Generally, symptoms appear between the first and second decade of life, although the full clinical presentation may emerge later. The severity of the disease can range from very mild cases that go unnoticed to substantial weakness and disability. Affected individuals typically experience weakness in the distal muscles, symmetric wasting (mainly in the peroneal muscles), and diminished or absent tendon reflexes. Sensory deficits, including impaired position sense, vibration sense, and pain/temperature sensation, are common in the feet and may later affect the hands. Pes cavus (high arches) or planus (flat feet) with hammer toes are often observed from childhood. Scoliosis of varying degrees may develop during adolescence. CMT1A is caused by duplications of a 1.4 Mb segment or point mutations in the PMP22 gene located on chromosome 17p12. Diagnosis of CMT1 is based on progressive motor and sensory neuropathy, slow nerve conduction velocity (NCV) with motor NCV less than 38 m/s in the upper limbs, and positive family history (although sporadic cases can occur due to new mutations). Genetic testing is the definitive method for diagnosis. Differential diagnosis should consider other genetic neuropathies, particularly X-linked CMT, autosomal dominant CMT2, CMT4, and hereditary neuropathy with liability to pressure palsies. CMT1 progresses slowly and affected individuals experience long periods of stability without noticeable deterioration. Most patients maintain their ability to walk throughout their lives and have an average life expectancy.
- CMT1A was the most common subtype of CMT, with a prevalence rate of 1 per 5000.
Thelansis’s “Charcot-Marie-Tooth Disease Type 1A (CMT1A) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Charcot-Marie-Tooth Disease Type 1A (CMT1A) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Charcot-Marie-Tooth Disease Type 1A (CMT1A) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Charcot-Marie-Tooth Disease Type 1A (CMT1A) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment